Every 8-K that Privia Health Group, Inc. (PRVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PRVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRVA filings page.
Privia Health Group, Inc. reported that its Board of Directors elected Opella Ernest, M.D. as a Class III director, effective September 1, 2026, and appointed her to the Board’s Compliance Committee on the same date. The Board determined she is independent under Nasdaq rules and disclosed no related-party arrangements or transactions requiring Regulation S-K Item 404(a) disclosure.
As a non-employee director, Dr. Ernest will receive an annual cash retainer under Privia’s Non-Employee Director Compensation Program and an annual equity grant of $200,000 in restricted stock units under the 2021 Omnibus Incentive Plan, with her initial grant pro-rated through the next annual stockholder meeting. Privia Health describes itself as a large physician enablement company operating in 25 states and the District of Columbia, supporting 1,300+ physician practices, serving 6.1+ million patients, and working with 5,600+ physicians and advanced practitioners.
Privia Health Group, Inc. reported strong second-quarter and year-to-date 2026 results, with total revenue of $632.6 million, up 21.4% from Q2 2025, and net income of $9.0 million, up 236.7%. Adjusted EBITDA, a non‑GAAP measure, increased 29.1% to $37.4 million.
Key operating metrics also expanded: Implemented Providers reached 5,644, Attributed Lives grew to 1,647,000, and Q2 Practice Collections rose to $970.0 million, supporting Care Margin of $132.1 million and Platform Contribution of $69.0 million. For the first six months of 2026, revenue was $1,236.5 million and Adjusted EBITDA was $74.1 million.
The company raised full‑year 2026 guidance for all key financial metrics, including Practice Collections of $3,650–$3,750 million, GAAP revenue of $2,350–$2,450 million, Care Margin of $515–$530 million, Platform Contribution of $260–$270 million and Adjusted EBITDA of $145–$155 million, and now expects Attributed Lives of 1,625,000–1,650,000. It expects approximately 70–80% of Adjusted EBITDA to convert to free cash flow in 2026, subject to timing of MSSP cash settlement, while maintaining cash and cash equivalents of $412.2 million at June 30, 2026.
Privia Health Group, Inc. announced that Shawn Morris resigned from its Board of Directors and from the Board’s Compliance Committee, effective July 6, 2026. The company states that his departure is not due to any disagreement regarding operations, policies, or practices.
The Board and the company thank Mr. Morris for his dedicated service and contributions during his tenure. The filing is signed on behalf of Privia Health Group, Inc. by Chief Executive Officer Parth Mehrotra.
Privia Health Group, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where all proposals were approved. Stockholders elected three Class I directors — Nancy Cocozza, David King, and Francis Soistman — to terms running until the 2029 annual meeting.
Stockholders also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 103,956,500 votes cast in favor. In addition, the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 received strong support, with 117,343,159 votes for and minimal opposition.
Privia Health Group, Inc. reported strong growth for the first quarter ended March 31, 2026. Total revenue reached $603.8 million, up 25.8% from $480.1 million, while gross profit rose to $125.6 million, a 21.2% increase. Operating income improved to $7.4 million, up 42.2%.
GAAP net income attributable to Privia declined to $3.1 million from $4.2 million, and diluted EPS slipped to $0.02 from $0.03, reflecting higher non-cash stock compensation of $21.9 million. Non-GAAP adjusted net income increased to $24.3 million from $19.9 million, with adjusted diluted EPS rising to $0.19 from $0.16.
Key operating metrics were solid: implemented providers grew to 5,535 (up 13.6%), Attributed Lives to 1,606,000 (up 26.5%), and Practice Collections to $914.8 million (up 14.6%). Adjusted EBITDA increased to $36.7 million, up 36.3%, with margin expanding to 28.5% of Care Margin.
Cash flow from operations was a use of $49.5 million, and cash and cash equivalents ended the quarter at $419.5 million. For full-year 2026, Privia reiterated guidance for revenue, Adjusted EBITDA and other metrics, and raised its Attributed Lives outlook to 1,600,000–1,625,000, expecting about 80% of Adjusted EBITDA to convert to free cash flow.
Privia Health Group reported strong fourth quarter and full-year 2025 results, with every major operating and financial metric at or above the high end of its guidance ranges. Full-year revenue reached $2,122.8 million, up 22.3%, while net income rose 59.3% to $22.9 million.
Non-GAAP adjusted net income grew 30.8% to $127.7 million, and adjusted EBITDA increased 38.8% to $125.5 million. Implemented providers grew 12.3% to 5,380 and attributed lives rose 22.7% to 1,541,000, supporting practice collections of $3,470.5 million.
Cash generation was robust, with net cash provided by operating activities of $163.4 million and year-end cash of $479.7 million and no debt. For 2026, the company guides revenue to $2,350–$2,450 million and adjusted EBITDA to $145–$155 million, implying roughly 15–24% EBITDA growth and about 80% conversion to free cash flow.
Privia Health Group, Inc. furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025. The company issued a press release on November 6, 2025, attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is stated as “furnished” and not “filed” under the Exchange Act. Privia Health’s common stock trades on the Nasdaq Global Select Market under the symbol PRVA.
Privia Health Group, Inc. (PRVA) reported the passing of Board member Patricia Maryland on October 24, 2025. She served on the Board for five years and was Chair of the Compliance Committee. The company expressed gratitude for her service and contributions.
The report is filed under Item 8.01 (Other Events) and was signed by Chief Executive Officer Parth Mehrotra. No additional board or committee actions are described in this disclosure.
Privia Health Group, Inc. (PRVA) filed a Current Report describing material risks and uncertainties affecting its business. The filing highlights regulatory and compliance exposure in a heavily regulated healthcare environment, the complexity of relationships with medical groups and Privia providers, and execution risks for its growth strategy and proprietary cloud-based technology rollout. It notes reliance on key vendors such as athenahealth, Inc., potential reimbursement rate pressure from government and private payers, cybersecurity and privacy risks related to protected health information, and workforce availability and cost pressures. The report references risk disclosures through year ended December 31, 2024 and states information is current as of the report date.